CD274 and neoplasm: Interestingly, progression to enzalutamide in mCRPC has been associated with an upregulation of tumor PD-L1, suggesting that PD-L1 might be a dynamic biomarker that is involved not only in immune evasion but also in resistance to enzalutamide [63].